YONKERS, N.Y., Jan. 27 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced that its spokesperson James
T. D'Olimpio M.D has been invited to attend and present at the 1st ISC
International Conference on Cancer Therapeutics Molecular Targets,
Pharmacology and Clinical Applications to be held in Florence, Italy, from
February 19 - 21, 2004.
As a consultant and member of the Scientific Advisory Board of ADVR,
Dr. D'Olimpio is involved in laboratory, translational and clinical research
in the field of drug treatment of cancer and has been invited to present a
poster and prepare an oral presentation at the conference. D'Olimpio's
abstract is entitled "Use of a Peptide Nucleic Acid Complex in Cancer
Regulation and Metastasis: A Preliminary Report of Bimodal Effects In Vitro"
and is on the basic scientific aspects of what has been discovered during
active "bench research" on AVR 118. Findings show that there appears to be
specific areas that can impact on a cancer cells ability to "change" into a
more normal cell or in the case of tumor cell invasion, hinder the cancer
cells ability to spread.
"It is a great honor to present at this conference and it is truly a
culmination of the in-depth laboratory work that is being done at ADVR to help
explain emerging data in clinical trials," said Dr. D'Olimpio. "We are
excited about this possibility as this conference is the perfect venue for
this kind of preliminary work. It is provocative and deserves further study."
The 1st ISC International Conference on Cancer Therapeutics, Molecular
Targets, Pharmacology and Clinical Applications will be held at Palazzo dei
Congressi, Piazza Adua 1, 50123 Firenze, Italy (http://www.firenze-expo.it).
ADVR's AVR118 represents a biopolymer chemistry that possesses novel
immunomodulator activity. This peptide-nucleic acid, which to date has shown
no indication of human toxicity, appears to stimulate the proinflammatory
responses required to combat viral infections such as AIDS and human
papillomavirus and to dampen aberrant autoimmune-type inflammatory responses,
such as occur in patients with rheumatoid arthritis. AVR118 is in clinical
trials in Israel for the treatment of cachexia (body wasting) in patients with
AIDS.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com. Advanced Viral Research Corp., based in
Yonkers, New York, is a biopharmaceutical firm dedicated to improving
patients' lives by researching, developing and bringing to market new and
effective therapies for viral and other diseases.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. There is no assurance that the Company will
be able to secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating to
clinical trials including obtaining adequate insurance on terms acceptable to
the Company or that if completed, clinical trials performed outside the United
States will assist the Company in obtaining FDA or other regulatory approval.
The Company undertakes no obligation to update or revise the information
contained in this announcement whether as a result of new information, future
events or circumstances or otherwise.
Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
Company News On-Call:
http://www.prnewswire.com/comp/903002.html
CONTACT:
Ronnie Welch or Kelly Cinelli, both of CWR &
Partners, +1-508-222-4802
|
